Biccard and Hughes factually support their proposal. Overall evaluation implies that succinylcholine should not be used in intensive care unit patients with bed rest beyond 1 week (disuse atrophy aggravated by other factors) or with administration of nondepolarizers beyond 5 days (pharmacologic denervation).
Biccard and Hughes graciously ignored my failure to cite their reference. 1Other work not cited further emphasizes the risk of altered skeletal muscle leading to sudden unexpected cardiac arrest at induction of anesthesia:
1. Hyperkalemic arrest and brain death occurred in a very ill 54-yr-old man given succinylcholine on his 35th hospital day, when recovery from quadriplegia of 14 months’ duration was incomplete. 2Plasma potassium was 9.8 mEq/l; he died 6 days after resuscitation.
2. Three obstetric patients with prolonged bed rest, given magnesium and ritodrine, had apparent hyperkalemic arrest when given succinylcholine. The mechanism is uncertain, but disuse atrophy was present, preanesthetic creatine kinase concentrations were increased, and membrane responses were perhaps altered by drug therapy. 3
3. Hyperkalemic asystole occurred in a child with Becker dystrophy within 3 min of exposure to halothane (no succinylcholine), with 250,000 IU creatine kinase. 4Brain death occurred eventually.
Inclusion of the succinylcholine-related data 1–3in table 1 of my article 5adds one denervation patient who died, 2two surviving intensive care unit patients, 1and three surviving miscellaneous category patients. 3New totals for the category of receptor up-regulation: 70 patients, 78 arrests, 9 deaths, and mortality now 11.5% rather than 11.1%. Hopefully, this mortality can be avoided.